{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "COVID-19",
      "adverse effects",
      "bamlanivimab",
      "casirivimab",
      "dosage",
      "efficacy",
      "etesevimab",
      "imdevimab",
      "safety"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33830966",
  "DateCompleted": {
    "Year": "2021",
    "Month": "04",
    "Day": "14"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "12",
    "Day": "07"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "1523-2859",
      "JournalIssue": {
        "Volume": "63",
        "Issue": "1621",
        "PubDate": {
          "Year": "2021",
          "Month": "Apr",
          "Day": "05"
        }
      },
      "Title": "The Medical letter on drugs and therapeutics",
      "ISOAbbreviation": "Med Lett Drugs Ther"
    },
    "ArticleTitle": "An EUA for bamlanivimab and etesevimab for COVID-19.",
    "Pagination": {
      "StartPage": "49",
      "EndPage": "50",
      "MedlinePgn": "49-50"
    },
    "PublicationTypeList": [
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "United States",
    "MedlineTA": "Med Lett Drugs Ther",
    "NlmUniqueID": "2985240R",
    "ISSNLinking": "0025-732X"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antibodies, Monoclonal, Humanized"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antiviral Agents"
    },
    {
      "RegistryNumber": "45I6OFJ8QH",
      "NameOfSubstance": "bamlanivimab"
    },
    {
      "RegistryNumber": "N7Q9NLF11I",
      "NameOfSubstance": "etesevimab"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [
        "administration & dosage",
        "adverse effects",
        "therapeutic use"
      ],
      "DescriptorName": "Antibodies, Monoclonal, Humanized"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "adverse effects",
        "therapeutic use"
      ],
      "DescriptorName": "Antiviral Agents"
    },
    {
      "QualifierName": [
        "diagnosis",
        "virology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Approval"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "drug effects",
        "genetics",
        "pathogenicity"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Treatment Outcome"
    },
    {
      "QualifierName": [],
      "DescriptorName": "United States"
    },
    {
      "QualifierName": [],
      "DescriptorName": "United States Food and Drug Administration"
    },
    {
      "QualifierName": [],
      "DescriptorName": "COVID-19 Drug Treatment"
    }
  ]
}